American Society of Hematology

Fig. 2.

$Fig. 2. MTX transport impairment of B-precursor and T-cell ALL blasts at diagnosis. MTX transport impairment was assayed with PT430 and flow cytometry and data are plotted as relative fluorescence ratios (ie, PT430 fluorescence with MTX to trimetrexate treatments) versus patient numbers for one or two separate blast subpopulations (designated S1 and S2). The higher Mtx/trimetrexate fluorescence ratios reflect impaired Mtx transport. Specimen numbers are from Tables 1 and 2. As described in Materials and Methods, normal Mtx transport was taken as fluorescence ratios of 1 to 1.2 and ratios in excess of 1.2 were considered impaired. For the 3 B-precursor specimens (10, 12, and 25) expressing heterogeneous Mtx transport, impaired Mtx transport was detected in only a small fraction of the total blasts (14%, 22%, and 16%, respectively).$

MTX transport impairment of B-precursor and T-cell ALL blasts at diagnosis. MTX transport impairment was assayed with PT430 and flow cytometry and data are plotted as relative fluorescence ratios (ie, PT430 fluorescence with MTX to trimetrexate treatments) versus patient numbers for one or two separate blast subpopulations (designated S1 and S2). The higher Mtx/trimetrexate fluorescence ratios reflect impaired Mtx transport. Specimen numbers are from Tables 1 and 2. As described in Materials and Methods, normal Mtx transport was taken as fluorescence ratios of 1 to 1.2 and ratios in excess of 1.2 were considered impaired. For the 3 B-precursor specimens (10, 12, and 25) expressing heterogeneous Mtx transport, impaired Mtx transport was detected in only a small fraction of the total blasts (14%, 22%, and 16%, respectively).

This Feature Is Available To Subscribers Only